Plasma KIM-1 levels may be a useful, noninvasive biomarker for risk prognostication in metastatic RCC. Circulating kidney injury molecule-1 (KIM-1) predicts survival outcomes in patients with ...
The clinical efficacy of enfortumab vedotin plus pembrolizumab in real-world patients is compatible with that of the phase 3 EV-302 clinical trial. Treatment with enfortumab vedotin plus ...
Amid a rapidly evolving landscape in the treatment of muscle-invasive bladder cancer (MIBC), new findings presented at the ...
According to investigators, there is no validated PSA-based endpoint to compare oncologic outcomes after radical prostatectomy and radiation therapy for localized prostate cancer.
A recent study explored the association between rectal spacer use and the US county-level prevalence of erectile dysfunction.
Lutetium 177-PSMA-617 is an appropriate alternative to cabazitaxel in patients with metastatic castration-resistant prostate cancer, resulting in better progression-free survival. Greater survival ...
Investigators assessed whether MRI alone can identify all cases of Gleason grade group 2 or higher disease in patients on ...
The FDA has approved Emblaveo with metronidazole for patients with complicated intra-abdominal infections and limited options.
Opioid prescriptions in the emergency department linked to small increases in hospital admission and subsequent opioid prescription use ...
Prevalence of preterm birth and low birth weight slightly higher, but no difference seen in prevalence of birth defects ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback